return to small text site

 

US
Europe
US
Europe

press releases

press coverage
electronic press kit
LX211
LX201

LX214

LX212
polymer technology
pipeline
other projects

uveitis

corneal transplantation
dry eye syndrome

age-related macular degeneration

mission
history
management
board of directors
investors

About

Ophthalmic Indications
Products &
Technologies

Partners

News & Media
Careers
Contact Us

 

  ABOUT LUX
 

Lux Biosciences is a clinical stage biotechnology company specialized in the field of ophthalmic diseases. We are developing novel medications to treat the underlying causes of ophthalmic diseases and alleviate their symptoms, and if approved by regulatory authorities, we plan to commercialize these products. With two first-in-class products currently in Phase 3 clinical development and several innovative, highly promising earlier stage projects, we have made significant progress towards building a revenue-generating, high-growth and sustainable ophthalmic company.

 

© 2008 Lux Biosciences, Inc. All rights reserved.                 Web Terms